These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21719304)

  • 1. Primary plasma cell leukemia in the era of new drugs: has something changed?
    Musto P; Pagano L; Petrucci MT; Morabito F; Caravita T; Di Raimondo F; Baldini L; Tosi P; Bringhen S; Offidani M; Omede' P; Neri A; D'Auria F; Bochicchio GB; Cavo M; Boccadoro M; Palumbo A
    Crit Rev Oncol Hematol; 2012 May; 82(2):141-9. PubMed ID: 21719304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation.
    Nishihori T; Abu Kar SM; Baz R; Alsina M; Harousseau JL; Kharfan-Dabaja MA
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1144-51. PubMed ID: 23416092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Plasma Cell Leukemia: Identity Card 2016.
    Musto P; Simeon V; Todoerti K; Neri A
    Curr Treat Options Oncol; 2016 Apr; 17(4):19. PubMed ID: 26995215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
    Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
    Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of bortezomib in patients with plasma cell leukemia.
    Musto P; Rossini F; Gay F; Pitini V; Guglielmelli T; D'Arena G; Ferrara F; Filardi N; Guariglia R; Palumbo A; ; ;
    Cancer; 2007 Jun; 109(11):2285-90. PubMed ID: 17469169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature.
    Saccaro S; Fonseca R; Veillon DM; Cotelingam J; Nordberg ML; Bredeson C; Glass J; Munker R
    Am J Hematol; 2005 Apr; 78(4):288-94. PubMed ID: 15795922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience.
    Lebovic D; Zhang L; Alsina M; Nishihori T; Shain KH; Sullivan D; Ochoa-Bayona JL; Kharfan-Dabaja MA; Baz R
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):507-11. PubMed ID: 21813352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary plasma cell leukemia 2.0: advances in biology and clinical management.
    Neri A; Todoerti K; Lionetti M; Simeon V; Barbieri M; Nozza F; Vona G; Pompa A; Baldini L; Musto P
    Expert Rev Hematol; 2016 Nov; 9(11):1063-1073. PubMed ID: 27759436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advances in the Diagnosis and Therapy of Primary Plasma Cell Leukemia -Review].
    Wang H; Li JY; Sun C; Zhou X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1837-1841. PubMed ID: 29262927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome.
    Ganzel C; Rouvio O; Avivi I; Magen H; Jarchowsky O; Herzog K; Cohen Y; Tadmor T; Horwitz NA; Leiba M; Nagler A; Cohen Y; Bulvik S; Polliack A; Rowe JM; Gatt ME;
    Leuk Res; 2018 May; 68():9-14. PubMed ID: 29501828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs.
    Morabito F; Gentile M; Mazzone C; Bringhen S; Vigna E; Lucia E; Recchia AG; Raimondo FD; Musto P; Palumbo A
    Eur J Haematol; 2010 Sep; 85(3):181-91. PubMed ID: 20491882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation].
    Li WJ; Wang FR; Wen L; Chen Y; Chen H; Huang XJ; Lu J
    Zhonghua Nei Ke Za Zhi; 2020 Oct; 59(10):801-806. PubMed ID: 32987483
    [No Abstract]   [Full Text] [Related]  

  • 13. [Primary plasma cell leukemia--a comprehensive analysis of 44 cases].
    Cai ZJ
    Zhonghua Zhong Liu Za Zhi; 1990 Jul; 12(4):314-7. PubMed ID: 2272272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma.
    Iriuchishima H; Ozaki S; Konishi J; Matsumoto M; Murayama K; Nakamura F; Yamamoto G; Handa H; Saitoh T; Nagura E; Shimizu K; Nojima Y; Murakami H
    Acta Haematol; 2016; 135(2):113-21. PubMed ID: 26505781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma cell leukemia: concepts and management.
    Liedtke M; Medeiros BC
    Expert Rev Hematol; 2010 Oct; 3(5):543-9. PubMed ID: 21083471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine.
    Simeon V; Todoerti K; La Rocca F; Caivano A; Trino S; Lionetti M; Agnelli L; De Luca L; Laurenzana I; Neri A; Musto P
    Int J Mol Sci; 2015 Jul; 16(8):17514-34. PubMed ID: 26263974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation].
    Hosono N; Yamauchi T; Nakamura T; Yamashita T; Ueda T
    Gan To Kagaku Ryoho; 2008 Mar; 35(3):533-7. PubMed ID: 18347412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How I treat plasma cell leukemia.
    van de Donk NW; Lokhorst HM; Anderson KC; Richardson PG
    Blood; 2012 Sep; 120(12):2376-89. PubMed ID: 22837533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Plasma cell leukemia].
    Ravinet A; Bay JO; Tournilhac O
    Bull Cancer; 2014 Nov; 101(11):1048-58. PubMed ID: 25418598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study.
    Wang H; Zhou H; Zhang Z; Geng C; Chen W
    Turk J Haematol; 2020 May; 37(2):91-97. PubMed ID: 31769277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.